(±)-(4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoic acid | 90780-52-2

• 物质功能分类: 生物化工 - 生化试剂
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (±)-(4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoic acid
• 英文别名: (±)-17-hydroxy-4Z,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid；17-hydroxy-4Z,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid；17-HDoHE；17-HDHA；17-hydroxydocosa-4Z,7Z,10Z,13Z,15E,19Z-hexaenoic acid；17-hydroxy DHA；(4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoic acid
• CAS: 90780-52-2
• 化学式: C₂₂H₃₂O₃
• 分子量: 344.494
• InChiKey: SWTYBBUBEPPYCX-VIIQGJSXSA-N

物化性质

• 沸点：
  505.1±50.0 °C(Predicted)
• 密度：
  0.995±0.06 g/cm3(Predicted)
• 溶解度：
  0.1 M Na2CO3：2 mg/mL； DMF：可混溶； DMSO：可混溶；乙醇：可混溶； PBS（pH 7.2）：0.8 mg/mL
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  25
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 储存条件：
  -20°C，密闭保存，并保持干燥。

制备方法与用途

17-HDHA是二十碳五烯酸的自动氧化产物。

反应信息

• 作为产物：
  描述：

  二十二碳六烯酸 在 sodium tetrahydroborate 、 lipoxidase from soybean 、 氧气 作用下， 以 乙醇 为溶剂， 生成 (±)-(4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoic acid
  参考文献：
  名称：

  消炎和促分解脂质介体16（R），17（S）-diHDHA的首次全合成

  摘要：

  衍生自二十二碳六烯酸（DHA）及其16-受体的抗炎和促分解脂质介体16（R），17（S）-diHDHA的首次全合成。描述了用于合成16（R），17（S）-diHDHA的两种合成方法。第一个策略从DHA开始，并使用酶促反应，钒催化的烯丙基环氧化和碱促进的环氧化物异构化。第二种方法利用从开始手性池策略2-脱氧d核糖建立手性中心; Wittig反应，温和的丙酮化物裂解和酯水解是合成的关键步骤。

  DOI：

  10.1016/j.tetlet.2018.02.029

文献信息

• Compositions comprising omega-3 fatty acids, 17-HDHA and 18-HEPE and methods of using same
  申请人：Solutex NA LLC

  公开号：US10653703B2

  公开（公告）日：2020-05-19

  The present invention relates to a polyunsaturated fatty acid composition comprising Omega-3 fatty acids, 17-HDHA and 18-HEPE. The composition can furthermore comprise DPA and/or an acceptable carrier and can be present in a capsule or other suitable dosage unit. The invention also relates to the process of obtaining the composition and methods for using same.

  本发明涉及一种多不饱和脂肪酸组合物，该组合物由 Omega-3 脂肪酸、17-HDHA 和 18-HEPE 组成。该组合物还可进一步包含 DPA 和/或可接受的载体，并可以胶囊或其他合适的剂量单位形式存在。本发明还涉及获得该组合物的过程以及使用该组合物的方法。
• WO2006/55965
  申请人：——

  公开号：——

  公开（公告）日：——
• [EN] 14-HYDROXY-DOCOSAHEXAENOIC ACID COMPOUNDS<br/>[FR] COMPOSITIONS À BASE D'ACIDE 14-HYDROXY-DOCOSAHEXAÉNOÏQUE
  申请人：BRIGHAM & WOMENS HOSPITAL

  公开号：WO2010033509A3

  公开（公告）日：2010-11-25
• Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same
  申请人：Nauroth Julie

  公开号：US20090318394A1

  公开（公告）日：2009-12-24

  Disclosed are compositions containing DHA and DPAn-6 and methods of administering and using the same to treat or prevent at least one symptom of inflammation or neurodegeneration or disease states associated with inflammation or neurodegeneration. Also discloses are compositions containing specific dosages and/or ratios of long chain polyunsaturated fatty acids that are particularly effective in reducing or preventing symptoms of inflammation or neurodegeneration.
• Oxylipins From Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same
  申请人：Arterburn Linda

  公开号：US20110178047A1

  公开（公告）日：2011-07-21

  Disclosed are novel oxylipins, referred to herein as docosanoids, that are derived from C22 polyunsaturated fatty acids, and method of making and using such oxylipins. Also disclosed is the use of docosapentaenoic acid (C22:5n-6) (DPAn-6), docosapentaenoic acid (C22:5n-3) (DPAn-3), and docosatetraenoic acid (DTAn-6: C22:4n-6) as substrates for the production of novel oxylipins, and to the oxylipins produced thereby. Also disclosed is the use of DPAn-6, DPAn-3, DTAn-6, and/or the oxylipins derived therefrom, and/or novel docosanoids derived from the structures of C22 fatty acids, in therapeutic and nutritional or cosmetic applications, and particularly as anti-inflammatory or anti-neurodegenerative compounds. The invention also relates to novel ways of producing long chain polyunsaturated acid (LCPUFA)-rich oils and compositions that contain enhanced and effective amounts of LCPUFA-derived oxylipins, and particularly, docosanoids.